by odysseyadmin | Feb 11, 2020 | Odyssey
Results from the ODYSSEY trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, USA. The trial team’s abstract titled “Adequate dolutegravir exposure dosed bid with rifampicin in children 6 to <18 years” has...
by Andrea Canton | Dec 20, 2019 | Odyssey
Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...
by Andrea Canton | Oct 23, 2019 | Odyssey
Recruitment to the main trial is complete! The ODYSSEY study has reached a major milestone by completing the recruitment of participants to the main trial. Recruitment of children ≥14kg is complete with a total of 707 participants randomised altogether: 311 recruited...
by Andrea Canton | Aug 26, 2019 | Odyssey
ODYSSEY presented at ‘Annual Conference of the International Society for Clinical Biostatistics’ in Leuven, Belgium We are pleased to report that a presentation from the ODYSSEY team at MRC CTU at UCL was well received at the 40th Annual Conference of the...
by Andrea Canton | Jul 30, 2019 | Odyssey
IAS 2019 – Oral abstract on ODYSSEY PK study presented at conference in Mexico City We are delighted to report that a late breaker oral presentation on the key PK substudy nested within the ODYSSEY trial was accepted and presented at the 10th IAS Conference on...
by Andrea Canton | Mar 14, 2019 | Odyssey
Adult dolutegravir could offer a practical and accessible treatment for children living with HIV Adult doses of an antiviral drug could offer a practical and accessible option for children weighing 20-25kg living with HIV. The results of the pharmacokinetic sub-study...
Recent Comments